Welcome to our dedicated page for Rocket Pharmaceu news (Ticker: RCKT), a resource for investors and traders seeking the latest updates and insights on Rocket Pharmaceu stock.
Rocket Pharmaceuticals, Inc. reports developments in rare-disease genetic medicines, including its commercial-stage therapy KRESLADI for pediatric patients with severe leukocyte adhesion deficiency-I and its broader pipeline of investigational gene therapies. Company updates commonly address FDA actions, clinical-program progress, regulatory submissions, and financial results tied to research, development, and commercial readiness.
Recurring news themes include the AAV cardiovascular portfolio, such as RP-A501 for Danon disease, RP-A601 for PKP2-arrhythmogenic cardiomyopathy, and RP-A701 for BAG3-related dilated cardiomyopathy. Rocket also reports capital and balance-sheet actions, including monetization of its Rare Pediatric Disease Priority Review Voucher, as well as presentations at healthcare conferences.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced two oral presentations and one poster presentation at the 62nd American Society of Hematology Annual Meeting, scheduled for December 5-8, 2020. The oral presentations will focus on clinical data for Fanconi Anemia and Leukocyte Adhesion Deficiency-I, while the poster will present preliminary data on Pyruvate Kinase Deficiency. These programs leverage Rocket's "Process B" manufacturing platform, and aim to address critical therapies for rare childhood disorders.
Rocket Pharmaceuticals (NASDAQ: RCKT) reported its Q3 2020 financial results, highlighting advancements across its gene therapy pipeline for rare childhood disorders. The company noted positive data from the RP-L201 trial for LAD-I and initiated a higher dose trial of RP-A501 for Danon Disease. Despite challenges posed by the pandemic, patient enrollment continued. Rocket's cash position stood at $228.7 million, expecting to fund operations through Q2 2022, yet reported a net loss of $29 million or $0.53 per share.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) presented promising clinical data at the ESID 2020 Meeting for its gene therapy candidates RP-L201 and RP-L401. The Phase 1/2 trial of RP-L201 for Leukocyte Adhesion Deficiency-I (LAD-I) showed significant therapeutic benefits, with patients achieving CD18 expression levels well above survival thresholds. RP-L401 for Infantile Malignant Osteopetrosis (IMO) also demonstrated preclinical efficacy, supporting its progression to a Phase 1 trial. These advancements indicate Rocket's potential to address critical unmet medical needs in severe pediatric disorders.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced two presentations at the European Society for Immunodeficiencies (ESID) 2020 meeting, scheduled from October 14-17, 2020. The oral presentation will update data from its Phase 1/2 trial of RP-L201 for Leukocyte Adhesion Deficiency-I (LAD-I), while an e-poster will present preclinical results for RP-L401 targeting Infantile Malignant Osteopetrosis (IMO). Both presentations highlight Rocket’s commitment to addressing significant medical needs in rare pediatric diseases.